share_log

NanoDimension Inc. Sells 56,222 Shares of Icosavax, Inc. (NASDAQ:ICVX)

NanoDimension Inc. Sells 56,222 Shares of Icosavax, Inc. (NASDAQ:ICVX)

納米科技股份有限公司出售 56,222 股伊薩瓦公司（納斯達克股份有限公司：ICVX）
Financial News Live ·  2022/08/24 13:51

NanoDimension Inc. lowered its position in Icosavax, Inc. (NASDAQ:ICVX – Get Rating) by 2.0% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 2,693,772 shares of the company's stock after selling 56,222 shares during the period. Icosavax accounts for 41.6% of NanoDimension Inc.'s portfolio, making the stock its largest holding. NanoDimension Inc. owned 0.07% of Icosavax worth $18,964,000 at the end of the most recent quarter.

根據最近向美國證券交易委員會提交的 13F 表格，納米維度公司在第一季度將其在 Iosavax 公司（NASDAQ：ICVX-獲得評分）的地位下調了 2.0%。本基金於期內沽出 56,222 股股份後，擁有該公司股票 2,693,772 股股份。Iosavax 佔納米維公司的 41.6%。s 投資組合，使股票成為其最大的持有量。在最近一季末，奈米維公司擁有伊沙瓦的 0.07%，價值 18,964,000 美元。

A number of other hedge funds have also recently added to or reduced their stakes in ICVX. Allspring Global Investments Holdings LLC bought a new stake in Icosavax during the fourth quarter worth approximately $138,000. New York State Common Retirement Fund boosted its position in Icosavax by 36.7% during the fourth quarter. New York State Common Retirement Fund now owns 8,340 shares of the company's stock worth $191,000 after purchasing an additional 2,240 shares during the period. ProShare Advisors LLC bought a new stake in Icosavax during the fourth quarter worth approximately $201,000. JPMorgan Chase & Co. boosted its position in Icosavax by 67.6% during the first quarter. JPMorgan Chase & Co. now owns 19,548 shares of the company's stock worth $138,000 after purchasing an additional 7,883 shares during the period. Finally, Swiss National Bank bought a new stake in Icosavax during the fourth quarter worth approximately $597,000. Institutional investors and hedge funds own 79.43% of the company's stock.

一些其他對沖基金最近也增加或減少了他們在 ICVX 的股份。全春全球投資控股有限責任公司在第四季度收購了 Iosavax 的新股份，價值約為 138,000 美元。紐約州共同退休基金在第四季度將其在 Iosavax 的地位提高了 36.7%。在此期間，紐約州共同退休基金現在擁有該公司股票的 8,340 股，價值 191,000 美元。保共享顧問有限責任公司在第四季度購買了伊薩瓦的新股份，價值約為 201,000 美元。摩根大通公司在第一季度提高了 67.6% 在伊索瓦的地位。摩根大通公司於期內額外購買 7,883 股股份後，現擁有該公司股票價值 138,000 美元的 19,548 股股份。最後，瑞士國家銀行在第四季度購買了伊薩瓦的新股份，價值約為 597,000 美元。機構投資者和對沖基金擁有該公司股票的 79.43％。

Get
取得
Icosavax
Iosavax
alerts:
警報：

Analyst Ratings Changes

分析師等級變更

Separately, Evercore ISI raised Icosavax from an "in-line" rating to an "outperform" rating and set a $18.00 target price for the company in a research report on Wednesday, June 29th.

另外，永可 ISI 提出 Iicosavax 從「在線」評級到「跑贏大市」評級，並在 6 月 29 日（週三）的研究報告中設置了 18.00 美元的目標價格為該公司。

Insider Activity

內幕活動

In other news, insider Douglas Holtzman sold 9,337 shares of the stock in a transaction that occurred on Monday, August 1st. The stock was sold at an average price of $6.64, for a total value of $61,997.68. Following the completion of the sale, the insider now directly owns 293,711 shares of the company's stock, valued at $1,950,241.04. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, insider Douglas Holtzman sold 9,337 shares of the firm's stock in a transaction on Monday, August 1st. The stock was sold at an average price of $6.64, for a total value of $61,997.68. Following the completion of the transaction, the insider now directly owns 293,711 shares of the company's stock, valued at $1,950,241.04. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Adam K. Simpson sold 7,017 shares of the firm's stock in a transaction on Monday, August 1st. The stock was sold at an average price of $6.64, for a total value of $46,592.88. Following the completion of the transaction, the chief executive officer now directly owns 293,772 shares of the company's stock, valued at $1,950,646.08. The disclosure for this sale can be found here. Over the last three months, insiders sold 23,706 shares of company stock valued at $159,363. 39.09% of the stock is owned by company insiders.
在其他消息中，內幕道格拉斯·霍爾茨曼在 8 月 1 日星期一發生的交易中出售了 9,337 股。該股票以 6.64 美元的平均價格出售，總價值 61,997.68 美元。出售完成後，內幕人士目前直接擁有該公司股票的 293,711 股股份，價值 1,950,241.04 美元。有關交易已在向證券交易委員會提交的文件中披露，該文件可透過此超連結查閱。在相關消息中，內幕道格拉斯·霍茲曼（Douglas Holtzman）在 8 月 1 日（週一）的一項交易中出售了該公司股票的 9,337 股。該股票以 6.64 美元的平均價格出售，總價值 61,997.68 美元。交易完成後，內幕人士現在直接擁有該公司股票的 293,711 股，價值 1,950,241.04 美元。銷售在向 SEC 提交的文件中披露，可以通過 SEC 網站訪問。此外，首席執行官亞當 ·K· 辛普森在 8 月 1 日（週一）的一次交易中出售了該公司股票的 7,017 股。該股票以 6.64 美元的平均價格出售，總價值為 46,592.88 美元。交易完成後，首席執行官現直接擁有該公司股票的 293,772 股股份，價值 1,950,646.08 美元。此次銷售的披露可以在這裡找到。在過去的三個月中，業內人士出售價值為 159,363 美元的 23,706 股公司股票。39.09％ 的股票由公司內部人士擁有。

Icosavax Stock Performance

伊薩瓦斯股票表現

Shares of ICVX traded up $0.41 during mid-day trading on Wednesday, hitting $6.06. The company's stock had a trading volume of 2,154 shares, compared to its average volume of 113,413. Icosavax, Inc. has a one year low of $4.00 and a one year high of $41.98. The firm has a market capitalization of $241.67 million and a PE ratio of -2.11. The stock's 50-day moving average is $7.67 and its two-hundred day moving average is $9.81.

ICVX 的股票在周三中間交易期間上漲了 0.41 美元，觸及 6.06 美元。該公司的股票交易量為 2,154 股，相比其平均交易量為 113,413。伊卡薩瓦公司擁有一年低點 4.00 美元，一年新高為 41.98 美元。該公司的市值為 2.67 億美元，私募股權比率為 -2.11。該股票的 50 天移動平均線為 7.67 美元，其 200 日移動平均線為 9.81 美元。

About Icosavax

關於伊卡薩瓦

(Get Rating)

(取得評分)

Icosavax, Inc, a biopharmaceutical company, develops vaccines against infectious diseases. The company, with the help of its virus-like particle (VLP) platform technology, focuses primarily on life-threatening respiratory diseases. Its products in pipeline include IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; IVX-A12, a respiratory syncytial virus (RSV) monovalent antigen candidate with RSV/human metapneumovirus (hMPV) bivalent target indication; IVX-241, a vaccine candidate with hMPV target; and IVX-411, an original receptor binding domain (RBD) sequence antigen with SARS-CoV-2 target indication and is under Phase 1/2 clinical trial.

Iosavax 公司是一家生物製藥公司，開發針對傳染病的疫苗。該公司在其類似病毒的粒子（VLP）平台技術的幫助下，主要專注於危及生命的呼吸道疾病。其生產線產品包括 IVX-121，一種具有 RSV 靶的疫苗候選藥物，正處於 1/1b 期臨床試驗；IVX-A12，呼吸道合胞病毒（RSV）單價抗原候選物，具有 RSV/ 人基特納烏獸（HMPV）雙價目標指示症；IVX-241，具有 HMPV 靶標的疫苗候選物；以及 IVX-411，原受體結合域指示（RBS-2）目標正在接受 1/2 期臨床試驗。

Featured Stories

特色故事

  • Get a free copy of the StockNews.com research report on Icosavax (ICVX)
  • NYSE Stocks Give Investors a Variety of Quality Options
  • Zoom Video Communications Valuation Is Realigned With Reality
  • The J.M. Smucker Company Proves Why Staples Are Outperforming
  • Will the Real Palantir Please Stand Up?
  • Foot Locker Just Because A Very Tempting Buy
  • 免費獲取有關伊薩瓦（ICVX）的研究報告
  • 紐約證券交易所股票為投資者提供多種優質選擇
  • 縮放視頻通信估值與現實重新調整
  • JM Smucker 公司證明了為什麼斯台普斯的表現優於
  • 真正的古典請站起來嗎？
  • 足部儲物櫃只是因為一個非常誘人的購買

Want to see what other hedge funds are holding ICVX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Icosavax, Inc. (NASDAQ:ICVX – Get Rating).

想看看其他對沖基金還持有哪些 ICVX？ 訪問 Holdingschannel.com 以獲取伊薩瓦公司（納斯達克：ICVX-獲取評級）的最新 13 樓文件和內幕交易。

Receive News & Ratings for Icosavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icosavax and related companies with MarketBeat.com's FREE daily email newsletter.

接收 Iosavax 日報的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收 Iosavax 及相關公司的最新新聞和分析師評級的簡明每日摘要。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論